In a move that may bode ill for the entire class of phosphatidylinositol 3-kinase (PI3K) inhibitors, the FDA has issued a warning against Secura Bio’s Copiktra (duvelisib), citing a 9 percent increased risk of death compared to standard treatment in patients with leukemia and lymphoma.
Source: Drug Industry Daily